Model inputs.

<p>Model inputs.</p

Cost-effectiveness analysis of ribotype-guided fecal microbiota transplantation in Chinese patients with severe <i>Clostridium difficile</i> infection - Fig 3

<p>QALYs loss (a) and total cost (b) of each strategy against variation of prevalence of ribotype 002.</p

Base-case results of expected mortality, cost, and quality-adjusted life-year (QALY) loss.

<p>Base-case results of expected mortality, cost, and quality-adjusted life-year (QALY) loss.</p

Cost-effectiveness analysis of ribotype-guided fecal microbiota transplantation in Chinese patients with severe <i>Clostridium difficile</i> infection - Fig 1

<p><b>Vancomycin treatment arm (a) and ribotype-guided FMT arm (b) of decision-analytic model for patients with severe CDI.</b> CDI: <i>Clostridium difficile</i> infection; FMT: fecal microbiota transplantation; ICU: intensive care unit.</p

Cost-effectiveness analysis of ribotype-guided fecal microbiota transplantation in Chinese patients with severe <i>Clostridium difficile</i> infection - Fig 2

<p>QALYs loss (a) and total cost (b) of each strategy against variation of patient acceptance rate to FMT.</p

Scatter plot of incremental cost against incremental QALYs of ribotype-guided FMT versus vancomycin treatment.

<p>Scatter plot of incremental cost against incremental QALYs of ribotype-guided FMT versus vancomycin treatment.</p

Figure 1. Maximum likelihood phylogenetic tree of ST239

The phylogeny was based on the SNPs of the core genomes. The tree was rooted by using MRSA FPR3757 USA300 as an outgroup

Simplified Decision Tree.

<p>Simplified Decision Tree.</p

Clustering analysis of the 11 miRNAs was performed using DataAssist 3.0v based on ΔCt-values of the TLDA results.

<p>Upregulated miRNAs are designated by various shades of red and down-regulated miRNAs by various shades of green. Clinical phenotypes are labelled in different colours: active MTB infection (red), latent infection (blue), and healthy controls (green).</p

Biological pathways potentially affected by the differentially expressed microRNAs of significance from macrophages of active MTB disease, LTBI and healthy controls.

<p>Biological pathways potentially affected by the differentially expressed microRNAs of significance from macrophages of active MTB disease, LTBI and healthy controls.</p